Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Income from Continuing Operations (2016 - 2025)

Cytosorbents (CTSO) has disclosed Income from Continuing Operations for 14 consecutive years, with 3506792.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 26.69% year-over-year to 3506792.0, compared with a TTM value of 11878453.0 through Sep 2025, down 673.83%, and an annual FY2024 reading of 16494206.0, down 124.92% over the prior year.
  • Income from Continuing Operations was 3506792.0 for Q3 2025 at Cytosorbents, up from 4231000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15339024.0 in Q4 2023 and bottomed at 12200837.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 4729060.74, with a median of 4677530.0 recorded in 2021.
  • The sharpest move saw Income from Continuing Operations plummeted 1273.27% in 2021, then soared 2102.15% in 2023.
  • Year by year, Income from Continuing Operations stood at 9307012.0 in 2021, then surged by 91.77% to 766126.0 in 2022, then skyrocketed by 2102.15% to 15339024.0 in 2023, then tumbled by 117.36% to 2662303.0 in 2024, then tumbled by 31.72% to 3506792.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CTSO at 3506792.0 in Q3 2025, 4231000.0 in Q2 2025, and 1478358.0 in Q1 2025.